COMMUNIQUÉS West-GlobeNewswire

Iridex Completes Relocation of Manufacturing Facility to San Jose, California
05/10/2026
Company Expects to Realize Approximately $600,000 in Annualized Cost Savings SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile [...]
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
05/10/2026
TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced the closing of the [...]
Coave Therapeutics Presents Non-Human Primate Data Supporting Lead Wet AMD Gene Therapy Program at Euretina 2026
05/10/2026
New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher retinal and RPE-choroid expression than existing AAV capsids Aflibercept expressed via coAAV-SCS [...]
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
05/10/2026
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program HIGHLIGHTS Texas Ibogaine Research Corporation (“TIRC”), the [...]
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
05/10/2026
—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today [...]
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
05/10/2026
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options ZUG, Switzerland, Oct. 05, 2026 (GLOBE [...]
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
05/10/2026
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial [...]
Your Postal Code Shouldn’t Determine Your COPD Care. In Canada, It Still Does.
05/10/2026
Lung Health Foundation’s new Canadian COPD Performance Index finds significant shortfalls in COPD care across the country, driven by missing data, workforce shortages and no national strategy. Here’s where your region [...]
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
05/10/2026
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 ® (PCV20) and/or Capvaxive ® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31 [...]
Upgrade of revenue and operating profit guidance
05/10/2026
ANNOUNCEMENT NO. 317 5 October 2026 ChemoMetec maintained its positive momentum in the first quarter of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with the NC-203 being a [...]
Digbi Health Study of Nearly 16,000 Members Finds Precision Biology GI Care Delivers IBS Relief at Scale
05/10/2026
Combining Gut microbiome, genetic, and glucose signals delivers unprecedented personalized care to bring clinically meaningful relief to more than half of symptomatic members MOUNTAIN VIEW, Calif., Oct. 05, 2026 (GLOBE [...]
Flyte Aviation Launches Under NYSE American Ticker “VJET”
05/10/2026
Flyte Believes Its Proprietary Technology, Data, and Digital Booking Platform Can Disrupt the $11.6 Billion US Private Jet Charter Market Company believes its newly built AI-technology stack can fundamentally transform [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
05/10/2026
MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
05/10/2026
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Averly Health launches to transform cardiometabolic care in the UK
05/10/2026
Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will set a new standard for access and outcomes to transform the [...]
Elevate Holistics Launches Telehealth Platform for At-Home, Low-Dose Ketamine Care
05/10/2026
Tulsa, Oklahoma, Oct. 04, 2026 (GLOBE NEWSWIRE) -- Elevate Holistics , a telehealth provider focused on accessible, clinician-guided wellness care, announces the launch of its online ketamine telehealth platform, [...]
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
05/10/2026
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease MILAN, Oct. 04, 2026 (GLOBE [...]

Pages